Olivet Nazarene University

Digital Commons @ Olivet
Honors Program Projects

Honors Program

Spring 5-1-2019

Exploring the effects of protein kinase c-alpha gene
knockout on the proliferation of human embryonic
kidney cells
Emma J. Kuntz
Olivet Nazarene University, ejkuntz@olivet.edu

Follow this and additional works at: https://digitalcommons.olivet.edu/honr_proj
Part of the Biology Commons, and the Cell Biology Commons
Recommended Citation
Kuntz, Emma J., "Exploring the effects of protein kinase c-alpha gene knockout on the proliferation of human embryonic kidney cells"
(2019). Honors Program Projects. 107.
https://digitalcommons.olivet.edu/honr_proj/107

This Article is brought to you for free and open access by the Honors Program at Digital Commons @ Olivet. It has been accepted for inclusion in
Honors Program Projects by an authorized administrator of Digital Commons @ Olivet. For more information, please contact
digitalcommons@olivet.edu.

EXPLORING THE EFFECTS OF PROTEIN KINASE C-ALPHA GENE KNOCKOUT ON THE
PROLIFERATION OF HUMAN EMBRYONIC KIDNEY CELLS

By
Emma J. Kuntz

Honors Scholarship Project
Submitted to the Faculty of
Olivet Nazarene University
for partial fulfillment of the requirements for
GRADUATION WITH UNIVERSITY HONORS

December, 2018
BACHELOR OF SCIENCE
In
Biology

____________________________
Scholarship Project Advisor (Printed)

_________________
Signature

____________
Date

____________________________
Honors Council Chair (Printed)

_________________
Signature

____________
Date

____________________________
Honors Council Member (Printed)

_________________
Signature

____________
Date

Acknowledgements
This project was made possible by financial support from the Samuel Mayhugh
Research Fund as well as the Honors Program and Biology Department at Olivet
Nazarene University. I would like to thank my mentor, Dr. Greg Long, for his guidance,
expertise, and constant support throughout this project and my time at ONU.
Throughout the last few years, I have experienced tremendous growth as a scientist and
an individual, and I owe much of it to him. I’d also like to give a special thank you to Dr.
Daniel Sharda for his assistance, review and support. Finally, I owe thanks to the entire
faculty of the Biology Department at Olivet Nazarene University for their sincere desire
to foster an environment of academic and spiritual growth. It has made such a
difference in my life – in my pursuit of science and my walk with Christ, and I am so
grateful.

ii

Table of Contents
Acknowledgements………………………………………………………………………………………………………..ii
List of Figures………………………………………………………………………………………………………………….v
Abstract…………………………………………………………………………………………………………………………vi
Introduction……………………………………………………………………………………………………………………1
Review of Literature……………………………………………………………………………………………………….2
PKCα function…………………………………………………………………………………………………….2
Gene knockout and human embryonic kidney cells…………………………………………….3
CRISPR-Cas9……………………………………………………………………………………………………….4
Cell proliferation and proliferative agents…………………………………………………………..5
Methodology………………………………………………………………………………………………………………….7
Generation of PRKCA knockout cells…………………………………………………………………..7
Western blot analysis of PKCα knockout……………………………………………………………8
Treatment with proliferative agents: sphingosine-1-phosphate and phorbol
ester……………………………………………………………………………………………………….9
Statistical analysis…………………………………………………………………………………………….10
Results………………………………………………………………………………………………………………………….11
Establishing a working concentration of puromycin…………………………………………11
Confirmation of knockout…………………………………………………………………………………12
Observations and cell counts for untreated cells………………………………………………13
Observations of cells treated with sphingosine and PMA…………………………………13
Discussion……………………………………………………………………………………………………………….……16

iii

Knockout or homozygosity?………………………………………………………………………………16
Role of PKCα in homeostatic proliferation………………………………………………..………18
Role of PKCα during induction of proliferation…………….……………………………………19
References…………………………………………………………………………………………………………………...20

iv

List of Figures
Figure 1. Puromycin dose response curve in HEK cells two days after treatment.…………11
Figure 2. RFP expression using fluorescent microscopy in transfected cells before and
after puromycin selection…………………………………………………………………………………12
Figure 3. Cell doubling times in PRKCA knockout and wild-type HEK-293 cells.…………….13
Figure 4. PKCα knockout cells treated with PMA and sphingosine exhibit reduced
viability over time……………………………………………………………………………………….….…15

v

Abstract
Signaling molecules have important roles in many cellular functions, but because
these pathways are incredibly complex, the exact mechanisms often remain unknown.
One signaling molecule, protein kinase C alpha (PKC), is involved in cell proliferation
and is expressed at high levels in many cancers. Interestingly, its activity as a tumor
promoter or tumor suppressor varies depending on the cell type for reasons not yet
fully understood. This study aimed to investigate the role of PKC in cell proliferation in
order to better understand its function as a signaling molecule. To asses this, a knockout
line was generated using CRISPR-Cas9 and human embryonic kidney (HEK) cells. After
confirmation of knockout, proliferation studies were conducted on untreated knockout
and wild-type cells and upon addition of 0-0.5 μg/mL of PMA and 0-5 μg/mL of
sphingosine-1-phosphate to induce proliferation. Our results indicate that compared
with wild-type cells, untreated PKCα knockout cells exhibited reduced proliferation and
had high percentages of cell death when treated with proliferative agents. This supports
the hypothesis that PKC knockout reduces proliferation in human embryonic kidney
cells and suggests that PKC has an important role in normal cell function in a tumorpromoting context.

Keywords: protein kinase C alpha (PKC), proliferation, cancer, knockout, cell signaling
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Introduction
Protein kinase C alpha (PKCα), a signaling molecule involved in many cellular
processes, has an important role in cell growth and proliferation. The exact details of
this pathway, however, are unknown, and further elucidation on the effects of PKC on
cell proliferation is needed. In this study, HEK cells were genetically modified using
CRISPR-Cas9 to generate a cell line lacking PKC. Together with a wild-type HEK cell line,
these knockout cells were treated with varying levels of proliferative agents, and
differences in the resulting growth rates were assessed. Developing a PKC gene
knockout cell line and assessing proliferation of these cells increases our understanding
of the PKC signaling pathway, helps to elucidate its involvement in cell growth and
division, and contributes to hypotheses of the role it may play in the abnormal
proliferation that is characteristic of cancer cells. In short, our findings contribute to the
foundation for future applications of PKC involvement in cell proliferation.
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Review of Literature
PKC function
Cancer is the result of uncontrolled cell growth and is the second largest cause of
death in the United States [5]. This abnormal cell growth is attributed to cancer-causing
mutations that typically involve malfunction of tumor-suppressor genes and the
activation of proteins involving cell proliferation. In fact, many cancers are known to
involve a mutation in TP53, a tumor-suppressor gene [12]. Without the proper function
of the protein produced by that gene, p53, cell growth and division are largely
unregulated [12]. This results in abnormal growth, often initiated by cell signaling
molecules that have a role in normal, non-cancerous cell proliferation. One of these
signaling molecules, an enzyme called protein kinase C alpha (PKCα), is activated in
normal cells by diverse signaling pathways. Various stimuli, often involving interaction
with a membrane, can lead to PKC involvement in differentiation, apoptosis, cellular
transformation, motility, cell growth, proliferation, and many other cellular functions
[13]. Importantly, PKC has been linked to proliferation, survival, differentiation and
motility in tumor growth, but can also act as a tumor suppressor depending on the
context [4]. In fact, past research has shown that PKC activation leads to the
progression of many cancers (for example, bladder and breast cancer), while it may act
as a growth-inhibitory kinase in others (such as colon cancer and non-small cell lung
cancer) [1], [4], [10]. Its role in cell proliferation as an application of tumor promotion is,
however, not well understood, but targeting PKC as a potential therapy for many
cancers has been suggested [4]. In order to understand more about how aberrant PKC
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signaling may be contributing to the rapid growth and division of cancer cells, a better
understanding of the functional diversity of its proliferative role in cells is needed.
Gene knockout and human embryonic kidney cells
There are two common methods used to understand protein function:
genetically modifying a cell line to render the gene nonfunctional, and utilizing drug
inhibition to block protein function. In the inhibition method, proteins are still present,
so although function is impaired, it is still possible for the drug-inhibited protein to
interact with binding partners. Drug inhibition often also has off-target effects [16], and
thus an agent used to inhibit PKC function may also interfere with molecules involved
in other proliferation pathways. For example, UCN-01 is a PKC inhibitor with antitumor applications, but because it does not work exclusively via the PKC pathway it
cannot be used to understand the specific role of PKC in proliferation and tumor
promotion [4]. In contrast, gene knockout prevents the production of the protein
altogether and eliminates the problems associated with inhibition. Because it exclusively
targets the gene that codes for a protein, gene knockout yields more specific results.
Knocking out the gene for PKC in human embryonic kidney (HEK) cells would generate
a cell line that could serve as a comparison to wild-type HEK cells with a normal
functioning PKC gene.
HEK cells are commonly used in cell biology and cancer research for many
reasons: they are easy to grow and transfect, relatively inexpensive, and tumorigenic
[15]. These properties make HEK cells a practical and meaningful tool for use in a study
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involving gene-knockout and cell proliferation. Additionally, PKC does not act as an
anti-proliferative factor in HEK cells, so this cell line serves as an excellent model for
better understanding the functional role of PKC in proliferation and tumor promotion
[13]. A common concern involving gene-knockout involves cell viability. Removing a
gene can have drastic effects and is often too significant of an alteration for the cells to
survive. In 2002, researches developed a method of targeting PKC isotypes in HEK-293
cells and demonstrated that subtype-specific differentiation was possible [6].
Specifically, they performed subtype-specific knockdown of PKC on HEK cells using short
interfering RNA and grew them in normal conditions. Although this is not the same as
gene knockout with CRISPR-Cas9, the survival of these HEK cells without active PKC
suggests that CRISPR-Cas9-generated PRKCA knockout HEK cells would be viable for use
in proliferation studies.
CRISPR-Cas9
CRISPR-Cas9 is a relatively new technology that can be used for gene knockout.
Since the first discovery of a CRISPR locus in 1993, CRISPR-Cas9 has been researched
extensively [7]. In 2013, researchers used it to genetically modify the genes of mice and
mark them with a fluorescent reporter. Analysis verified that the CRISPR-Cas9
mechanism rarely makes errors and the use of this technology in eukaryotic cells is
effective, efficient, and accurate [17]. Continuing this work, in 2014 CRISPR-Cas9 was
successfully used for gene knockout in HEK-293 cells [18]. Similarly, this system could be
employed to create a HEK cell line without PRKCA, the PKC gene. Because of its use
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and reliability in genetic modification, CRISPR-Cas9 is important for cancer research and
understanding the role of specific proteins, such as PKC, in cell proliferation.
Additionally, our use of CRISPR-Cas9 in this study makes this method accessible as a
research and teaching tool at Olivet. The successful use of the CRISPR-Cas9 mechanism
will contribute to the development of laboratory protocol so that this tool could be
widely used by Olivet biology students.
Cell proliferation and proliferative agents
PKC isoforms are classified into several groups. PKC falls into the category of
classical PKCs (cPKCs). cPKCs are activated at a C1 domain and a C2 domain. The C1
domain is activated by diacylglycerol (DAG), a secondary messenger that is stimulated
by membrane receptors, and the C2 domain allows for the binding of other molecules in
the presence of calcium [13]. A phorbol ester, such as phorbol 12-Myristate 13-Acetate
(PMA), is a proliferative agent known to utilize the PKC pathway by binding at the C1
domain [11]. Another proliferative agent, sphingosine-1-phosphate, causes proliferation
independent of PKC signaling [2]. The mechanism of proliferation via PKC can differ
depending on the cell type and activity. Activated PKC has been documented to
upregulate cyclin-D1, cdk4 and p21cip1, all of which can enhance proliferation [13].
Commonly, PKC phosphorylates Raf-1, which leads to the activation of ERK-MAPK
(extracellular signal-regulated kinase-mitogen-activated protein kinase cascade) [13].
This enhances proliferation in many cell types, including HEK-293 cells [19]. PKCα
dependent and independent proliferation in HEK cells can be evaluated through visual
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observation and the generation of a cell growth curve with doubling times. This can be
calculated using a Hemocytometer over a period of several days. In order to evaluate
the effects of proliferative agents on cell proliferation, cells can be treated with various
concentrations of the proliferative agent, counted, and then used to construct a
concentration vs. cell proliferation curve.
PKC has an important role in cell proliferation, but it is functionally diverse and
largely not understood. Because of its involvement in tumor promotion, understanding
this protein and its signaling pathway is important and relevant for cancer research and
treatment. Investigating the effects of PRKCA knockout on proliferation in a cell line
where PKC is not tumor-suppressive can help fill this gap in research. Specifically,
attempting to induce abnormal proliferation by mechanisms that are PKC independent
and dependent in a PRKCA knockout cell line will yield further understanding of its exact
role in tumor promotion. We hypothesized that proliferation studies of wild-type and
knockout cells under both normal conditions and when treated with PKC-independent
and PKC-dependent proliferation agents would demonstrate that knocking out protein
kinase C-alpha reduces proliferation in HEK-293 cells.
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Methodology
Generation of PRKCA knockout cells
PRKCA knockout cells were produced following the manufacture protocol
provided by Santa Cruz Biotechnology [3]. Briefly, HEK-293 cells were seeded at a
density of 50,000 cells/well and grown in 24-well culture dishes in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum. Approximately 48
hours later, cells reached 60-75% confluence, and culture media was replaced with
media generated for optimal transfection of HEK-293 cells [14]. This media contained
both the CRISPR-Cas9 KO plasmid and the homology-directed repair (HDR) plasmid with
a fluorescent tag and also a puromycin-resistant gene insert prepared according to the
manufacture’s protocol [3]. Briefly, three tubes were incubated then combined and
added to each well. Tube A contained 240 μl of Optimem medium and 3.2 μg of the
CRISPR-Cas9 KO plasmid. Tube B contained 240 μl of Optimem medium and 3.2 μg of
the HDR plasmid. Tube C contained 400 μl of Optimem medium and 16 μl of
Lipofectamine 2000. These tubes were incubated individually for 5 minutes at room
temperature, then mixed gently and the combined solution was incubated for 20
minutes at room temperature. Following incubation, 115 μl of the final solution was
added to each well (12 total) with rocking. After 24 hours, this media was replaced with
standard DMEM and cells were grown in normal culture conditions.
Approximately 7 days post-transfection, cells were observed with fluorescent
microscopy to confirm transfection efficiency by fluorescence. Cells were then grown
and treated with 2.5 μg/mL of puromycin to kill cells lacking the transfected puromycin-
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resistant gene insert. This selected for cells likely to be PRKCA knockout cells. After
growing cells for an additional 7 days, they were treated with 10 μg/mL of puromycin to
select for highly-expressing homozygous knockout cells.
Western blot analysis of PKCα knockout
Puromycin resistant cells were grown and tested for PKC presence using
standard Western blot techniques [8]. Wild-type and knockout cells were grown in
normal conditions in 6-well culture dishes until they reached confluence. Upon reaching
confluence, cells were washed with PBS and treated with a lysis buffer containing RIPA
buffer (Sigma R0278) and four protease inhibitors: PMSF (100mM), Luepeptin (10
mg/mL), Aprotinin (10 mg/mL), and Pepstatin A (1mg/mL). Lysed cells were collected,
washed and centrifuged, and a BCA assay was performed to determine protein
concentration in the cell lysate for wild-type and knockout cells. Lysates were diluted to
a concentration of 1 mg/mL with SDS-PAGE loading buffer. 10% SDS-PAGE gel (Lonza)
was loaded with 20 μl of cell lysate per lane. Three lanes were loaded for each cell type,
and two lanes were loaded with protein molecular weight ladders. This procedure was
run at a constant voltage of 125 V for approximately 90 minutes. Western blot protocol
was taken from the Xcell II Blot Module User’s Manual. Transfer to the Western blot
membrane was performed overnight in a cold room at a constant voltage of 12 V.
Following this, the membrane was removed, treated with blocking buffer, and
incubated in primary antibody overnight. Primary antibody was prepared at a dilution of
1:500. Following this, the membrane was washed and treated with the secondary
antibody for 1 hour. The secondary antibody was prepared at a dilution of 1:12,500.
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Remaining western blot procedures took place in a photography dark room. The
membrane was incubated in ECL Western Blotting Substrate (ThermoFischer) then
exposed to film for times ranging from 10 to 45 seconds. Film was developed in
developer solution for 2-3 minutes, placed in water for 30 seconds, placed in fixer for 3
minutes, and then rinsed under running water for 5 minutes.
Treatment with proliferative agents: sphingosine-1-phosphate and phorbol ester
PRKCA knockout and wild-type HEK-293 cells were first grown in normal
conditions to determine viability and disruption of the normal cell cycle. Cells were
grown in the absence of puromycin to prevent altered proliferation compared to wildtype cells. Cell counts were recorded for each group in duplicate over a 4 day period.
Next, knockout and wild-type cells were treated with proliferative agents. The first of
these proliferative agents, sphingosine-1-phosphate, is known to work via PKCindependent mechanism in HEK-293 cells [2]. Knockout and wild-type cell cultures were
treated with concentrations of sphingosine-1-phosphate ranging from 0-5 μg/mL, and
observations of percent confluence were recorded. The second proliferative agent,
phorbol ester, is known to activate PKCα by mimicking diacylglycerol, the physiological
ligand for PKC that binds along with calcium for normal PKC activation [11]. Unlike
diacylglycerol, phorbol ester does not also require the binding of calcium to induce
proliferation [11]. Knockout and wild-type cell cultures were treated with
concentrations of phorbol ester ranging from 0-0.5 μg/mL, and observations of percent
confluence were recorded.
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Statistical analysis
A student’s t-test was used to assess significance of PKCα in cell proliferation,
with a p-value less than or equal to 0.05 considered statistically significant.
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Results
Establishing a working concentration of puromycin
In order to select for potential knockout cells using puromycin, it was important
to establish a minimum level of puromycin that is toxic to wild-type HEK-293 cells. Based
on previous literature, a treatment was conducted using concentrations of 0, 2, 2.5 and
3 μg/mL puromycin. Within two days of treatment, concentrations of 2.5 and 3 μg/mL
resulted in 100% cell death. A puromycin concentration of 2.5 μg/mL was then selected
to be used to treat transfected cells.

Puromycin Dose Response Curve in HEK Cells
Percentage of Cell Death

120
100
80
60
40
20
0
0

0.5

1

1.5

2

2.5

3

3.5

Concentration of Puromycin (μg/mL)

Figure 1. Puromycin dose response curve in HEK cells two days after treatment. Cells
were treated with concentrations of 0, 2, 2.5 and 3 μg/mL of puromycin. A
concentration of 2.5 μg/mL resulted in 100% cell death.
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Confirmation of knockout
All cells were observed for RFP expression 24 hours after transfection. As
expected, wild-type cells demonstrated a complete absence of RFP expression, and RFP
was observed at varying levels in transfected cells. Transfected cells treated with 2.5
μg/mL of puromycin resulted in some cell death, but surviving cells displayed normal,
healthy growth. Control cells were treated simultaneously with 2.5 μg/mL puromycin
and resulted in 100% cell death. The remaining transfected cells were then observed
under fluorescent microscopy to analyze RFP expression. Figure 2 shows photographs
depicting RFP expression in transfected cells before treatment with puromycin and one
week post-treatment.

A

B

Figure 2. RFP expression using fluorescent microscopy in transfected cells before and
after puromycin selection. Few transfected cells expressed RFP before puromycin
selection (A), and RFP was observed at much higher levels in transfected cells after
selection with puromycin (B).
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Observations and cell counts for untreated cells
To monitor the general health of the knockout cell line, observations were made
in comparison to wild-type HEK-293 cells. Transfected cells maintained consistent
appearances with the wild-type cells and grew without much difficultly. They did,
however, appear to grow at a slower rate than control cells. Cell counts were recorded
to confirm this observation, where the cell doubling time of wild-type HEK-293 cells was
determined to be 1.11 ± 0.04 days, while the doubling time of PRKCA KO cells was over
twice as long at 2.27 ± 0.44 days (Figure 3, p=0.045).

Average Doubling Time (days)

3
2.5
2
1.5
1
0.5
0

Wild -Type

Knockout

Figure 3. Cell doubling times in PRKCA knockout and wild-type HEK-293 cells.
Doubling times were calculating from cell counts over a four day period. Wild-type:
mean = 1.11 days, SE = 0.04. KO: mean = 2.27 days, SE = 0.44.

Observations of cells treated with sphingosine and PMA
As quiescent PRKCA knockout cells grew more slowly, we also sought to
determine if inducing proliferation would result in aberrant growth in PRKCA knockout
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cells. Treatments with sphingosine (Figure 4A) and PMA (Figure 4B) were completed. As
demonstrated in Figure 4, these observations resulted in very high levels of growth for
control cells treated with all concentrations of PMA and sphingosine. All wild-type cells
reached confluence within 48 hours (data not shown). Contrary to this observation,
transfected cells treated with PMA and sphingosine did not demonstrate observable
growth within 48 hours. By 96 hours (four days), treated transfected cells demonstrated
high levels of death ranging from 75-100% (Figure 4A and 4B). These results indicate
that PKCα plays a central role in proliferative induction by both PMA and sphingosine
signaling pathways.
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A

Percent Confluence in Wild-Type and Knockout
Cells Treated With Sphingosine
Percent Confluence
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Percent Confluence in Wild-Type and Knockout
Cells Treated With PMA
Percent Confluence
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Figure 4. PKCα knockout cells treated with sphingosine (A) and PMA (B) exhibit
reduced viability over time. A: Cells were treated with concentrations of 0, 0.1, 1 and
5 μg/mL of sphingosine-1-phosphate. B: Cells were treated with concentrations of 0,
0.162, 0.3 and 0.5 μg/mL of PMA. Confluence was assessed four days post-treatment
and was observed in two cell culture wells for each cell type and treatment group.
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Discussion
Determination of the role of PKC in cell proliferation was desired, so the PRKCA
gene knockout was attempted, growth in normal conditions assessed, and the effects of
treating knockout cells with PKC-dependent and independent proliferation agents
observed.
Knockout or homozygosity?
Within 2 days of transfection, RFP expression was observed in transfected cells in
varying amounts. Some of this can be attributed to the fact that transfection was not
successful in all treated cells. In cells displaying at least some level of RFP, however, one
possible explanation for differing levels of expression involves transient expression of
the HDR plasmid. Transient expression occurs when the plasmid has not been
incorporated into the genome but is actively being transcribed. To account for this
possibility, transfected cells were grown for an additional two weeks and underwent an
additional puromycin treatment. Because transient expression of the HDR plasmid from
Santa Cruz Biotechnology lasts a maximum of seven days, any expression of RFP over
two weeks post-transfection should be attributed exclusively to genomic expression of
the plasmid [3]. The vast majority – approximately 90-95% – of remaining cells
demonstrated RFP after this additional treatment, which very strongly suggested
transfection success.
Western blot analysis detected PKC expression in both cell lines (data not
shown). Bands were observed around 80 kDa, the molecular mass of PKC and other
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isoforms of PKC, in lanes containing wild-type cell lysate as well as lanes containing
knockout cell lysate. There were no noticeable differences in size or expression between
the bands in any exposure times. Though this appeared to contradict other indicators of
knockout success, there are many possible explanations for this observed result. The
quantity of secondary antibody appropriate for use in this procedure was estimated
based on previous literature; however, it is highly likely that the amount used was too
high and resulted in non-specific binding. Because the secondary antibody contains the
horseradish enzyme that indicates expression during x-ray exposure, non-specific
binding of this antibody to other forms of PKC would yield similar band expression on
the final x-ray film and result in a false positive. Future studies could replicate this
procedure with varying levels of secondary antibody to yield more meaningful results.
An additional explanation for varying levels of expression in RFP positive cells
and the Western blot result involves the genomic location of RFP. Expression of PKC is
biallelic. Because of this, transfected cells may have been a combination of hemizygous
and homozygous PRKCA knockout cells. In an attempt to select for highly-expressing
homozygous knockout cells, we treated transfected cells with 10 g/mL of puromycin
(four times the concentration that is toxic to wild-type cells) before conducting
proliferation studies. Cells that survived this treatment were determined to be probable
knockout cells and were used for all remaining procedures, however it is still possible
that some of these surviving cells were hemizygous knockout, and this could explain the
observed expression of PKC in the Western blot analysis.
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Role of PKCα in homeostatic proliferation
Cell growth calculations yielded doubling times of 1.11 ± 0.04 days and 2.27 ±
0.44 days for untreated wild-type cells and knockout cells, respectively. HEK cells are
typically expected to have a doubling time of 24 hours, so the calculation of
approximately a one day doubling time for wild-type cells is consistent with previous
literature. A statistical analysis comparing the mean doubling times resulted in a p-value
of 0.045. This suggests that the doubling time of PRKCA knockout cells is significantly
slower than the doubling time of wild-type cells. Upon further analysis of the data, there
are two main factors that contributed to the p-value: the small sample size and the high
level of variance in knockout cells. Though all individual doubling times for knockout
cells were slower than wild-type cells, they were less consistent. They appeared to take
an especially long time to grow immediately after attachment. This observation is
important in our understanding of how PRKCA knockout influences proliferation in HEK
cells and how varying growth among knockout cells effects the significance of the data.
Overall, observations and cell counts consistently demonstrated reduced proliferation in
knockout cells, and a statistical analysis of the data yielded a significant result. In further
studies, this data should be replicated with a larger sample, but our preliminary data
demonstrating slowed growth supports the hypothesis that PRKCA gene knockout
reduces proliferation in HEK cells.
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Role of PKCα during induction of proliferation
Treatments of knockout cells in high concentrations of sphingosine and PMA
resulted in abnormal levels of cell death. This result was observed in two cell culture
wells for each group alongside treatment of the same concentrations on wild-type cells
that experienced rapid growth and reached confluence. To assess the significance of this
data, it should be replicated with a larger sample size and a wider range of
concentrations for each proliferation agent. However, we are still able to discuss several
possible explanations for this observation within our study. Cells that have experienced
gene knockout are often less stable; gene knockout is an intensive process, and a
protein such as PKC is important in many cell processes [4]. Inducing proliferation in
these cells may be received as a stressful signal that the weakened cell cannot endure.
Additionally, PKC often acts as an anti-apoptotic factor, restricting the cell’s tendency
to default toward death [13]. Cells without PKC are, then, more likely to begin to
progress toward apoptosis after receiving an external cellular signal. Because HEK cells
are tumorigenic and PRKCA knockout cells became apoptotic when stimulated with high
concentrations of proliferation agents, these data suggest that PKC is important for
normal cell function in a tumor-promoting context. Moreover, since untreated PRKCA
knockout cells grew significantly slower than wild-type cells, together, these data
further highlight the importance of PKCα as a key regulator of cellular proliferation.
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